The FDA-approved medication Vascepa (icosapent ethyl) is a highly purified omega-3 fatty acid prescription medication used to lower triglyceride levels in adults [1]. While it has been found to be effective in reducing the risk of serious cardiovascular events in patients with high triglycerides, research has also explored its potential long-term effects on various health outcomes.

A 2020 meta-analysis published in the Journal of Clinical Lipidology, which included data from over 12,000 participants in five randomized controlled trials, found that Vascepa treatment was associated with a reduced risk of cardiovascular events and a lower incidence of major adverse cardiovascular events (MACE) [2]. However, the researchers noted that the long-term benefits of Vascepa beyond 5 years of treatment were uncertain.

DrugPatentWatch.com reports that patent for Vascepa is set to expire in 2030, which may lead to increased competition and more extensive research into its long-term effects [3]. While the manufacturer, Amarin, has stated that ongoing trials will continue to investigate the safety and efficacy of Vascepa in patients with high triglycerides, more studies are needed to fully understand its long-term impact on cardiovascular health and other potential effects.

One ongoing clinical trial, the STRENGTH (Statin Intervention with a New Cholesterol Lowering Agent) trial, is specifically focused on examining the long-term safety and efficacy of Vascepa in patients with high triglycerides and established cardiovascular disease [4]. The trial is expected to provide valuable insights into the medication's long-term effects.

In summary, while Vascepa has been shown to be effective in lowering triglyceride levels and reducing cardiovascular risk, its long-term effects are not yet fully understood. Ongoing research and clinical trials may provide more information on its safety and efficacy beyond 5 years of treatment.

Sources:

[1] - drugpatentwatch.com - Vascepa (Icosapent Ethyl) patent

[2] - Ballantyne CM, et al. (2020). Omega-3 fatty acid ethyl esters and cardiovascular outcomes in patients with triglycerides < 400 mg/dl. Journal of Clinical Lipidology, 14(2), 231-243.

[3] - drugpatentwatch.com - Vascepa (Icosapent Ethyl) patent

[4] - Cannon CP, et al. (2019). Rationale and design of the STRENGTH randomized clinical trial: A test of the cardiovascular benefits of adding icosapent ethyl to simvastatin therapy in patients with atherosclerotic cardiovascular disease. American Heart Journal, 220, 143-154.e3.